NKF May 1 - 2026 Supporting materials POSTER: Impact of SGLT2i Use on Sibeprenlimab Outcomes in IgA Nephropathy (IgAN): Subgroup Analysis From the Phase 3 VISIONARY Trial Interim Analysis POSTER: Evaluation of Immunoglobulin G Reduction and Infection Incidence in an Interim Analysis of the Phase 3 VISIONARY Trial of Sibeprenlimab in IgA Nephropathy POSTER: Comparative Network Meta-Analysis (NMA) of Sibeprenlimab Efficacy in the Treatment of Immunoglobulin A Nephropathy (IgAN) POSTER: “I Feel Trapped. It’s Lifelong”: Understanding the Patient Experience of IgAN POSTER: Sibeprenlimab in IgA Nephropathy: Achievement of Target Proteinuria Thresholds in the Phase 3 VISIONARY Trial Interim Post Hoc Analysis PRESENTATION: Sibeprenlimab in IgA Nephropathy: Achievement of Target Proteinuria Thresholds in the Phase 3 VISIONARY Trial Interim Post Hoc Analysis POSTER: What Treatment Factors Matter Most to Patients with IgA Nephropathy? Insights from a Multi-Country Discrete Choice Experiment
